optimal temperature in vivo
Bilal Zia Chaudhry, a graduate from the School of Architecture and Design in Oslo has worked with Otivio AS to develop an improved solution for Otivio’s patient cooling system.
For more information see:
Press release: http://www.norway.org.sg/News_and_events/norwaysingapore/Norwegian-Designer-wins-Red-Dot-Design-Award-Design-Concept-2010-in-Singapore/
Youtube clip: http://www.youtube.com/watch?v=jDjMWf9c_sA
Otivio AS strengthens its IP protection on a medical device for controlling patient temperature.
OSLO (Sept. 1, 2010) – Otivio AS develops medical devices and solutions for patient temperature control. The patent application entitled: “Device for applying pulsating pressure to a local area of the body and the applications thereof” describes the invention done by Dr. Erling Rein and Dr. Marius Filtvedt enabling the use of an oscillating negative pressure to increase blood flow to the skin of a limb. The increased blood flow allows efficient heat transfer to or from the blood of a patient. By heating or cooling the blood in a limb, the circulating blood ensures heating or cooling of the whole body. The system is non-invasive and can be used to heat or cool non-anesthetized patients.
Otivio also owns issued patents in Europe and other countries covering the same technology. This patent is important as the US market is significant, the number of stroke patients in the US is increasing and it is important to have proper protection as we finalize the development of our lead product prior to entering the US market.
“I’m extremely pleased with the notice of allowance for this US patent as it provides us
with a strong protection for our lead technology. It confirms our leadership position in the field and we will continue to diligently develop the product in order to bring a solution to patients in a timely manner” said Iacob Mathiesen, Chief Executive Officer of Otivio.
The company is currently performing a clinical trial using this technology to prevent fever in stroke patients. Prevention of fever in patients with acute stroke has been shown to reduce loss of neurological function after an acute stroke. It has also been proven highly effective in saving lives and preventing neurological damage after cardiac arrest and after oxygen deprivation in newborns. This trial will look specifically at whether Otivio’s non-invasive cooling system can be used safely in awake elderly stroke patients.
About Otivio
Based on advanced understanding of circulation physiology and medicine, originally developed at the University of Oslo, Norway, Otivio develops treatment solutions and instruments that maintain optimal body core temperature in patients, and thereby improve patient survival and recovery rates. The company initiated a clinical trial in stroke patients in Q3 2010 with the goal of preventing hyperthermia (fever). The technology has also been used to prevent hypothermia in anesthetized patients and to prevent hyperthermia in an experimental setting. Devices and procedures for therapeutic cooling constitute a rapidly growing market.
###
Otivio AS granted NOK 1.2 mill to support new applications of its core technology for patient temperature control.
OSLO, March 1., 2010
Otivio AS, an exclusive owner of patented technology to increase blood flow to a patient’s limb and its use for controlling and altering a patient’s temperature, announced today that it has been awarded a NOK 1.2 million grant from the Research Council of Norway to explore new applications of the technology.
CEO Iacob Mathiesen said, “We are excited about the potential for Otivio’s proprietary technology and we are exited about this opportunity to further explore new ways to utilize our technology. The Company’s device for adjusting a patient’s core temperature has multiple potential applications. The technology has the potential to revolutionize the way a patient’s temperature is controlled and altered.
Mathiesen continued, “The NOK 1.2 million grant awarded from the Research Council of Norway represents an important contribution to the R&D costs that will be incurred during our effort to explore additional utilization of our technology and it represents a shared belief in our ability to develop and commercialize this revolutionary product.”
Otivio is currently focused on developing a device to prevent fever in stroke patients, the technology which is non-invasive and can be used without anesthesia is being tested in a clinical trial at Oslo University Hospital. Prevention of fever in patients with acute stroke has been shown to reduce loss of neurological function after an acute stroke. It has also been proven highly effective in saving lives and preventing neurological damage after cardiac arrest and after oxygen deprivation in newborns. This trial will look specifically at whether Otivio’s non-invasive cooling system can be used safely in awake elderly stroke patients.
About Otivio
Based on advanced understanding of circulation physiology and medicine, originally developed at the University of Oslo by Drs. Erling B. Rein and Marius Filtvedt, Otivio develops treatment solutions and instruments that maintain optimal body core temperature in patients, and thereby improve patient survival and recovery rates. The company initiated a clinical trial in stroke patients in Q3 2010 with the goal of preventing hyperthermia (fever). The technology has also been used to prevent hypothermia in anesthetized patients and to prevent hyperthermia in an experimental setting. Devices and procedures for therapeutic cooling constitute a rapidly growing market.
###